Clostridioides

DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020

Retrieved on: 
Giovedì, Novembre 12, 2020
Medical specialties, Clostridiaceae, Gram-positive bacteria, Microbiology, Infectious diseases, Antibiotic-resistant bacteria, Clostridioides difficile, CDI, Clostridioides, COVID-19 pandemic

Patients enrollment is ongoing in this Phase II trial despite a disrupted context due to the COVID-19 outbreak.

Key Points: 
  • Patients enrollment is ongoing in this Phase II trial despite a disrupted context due to the COVID-19 outbreak.
  • 40% of patients suffering a Clostridioides difficile infection (CDI) have severe forms, associated with high morbidity and mortality rates.
  • DEINOVE is a French biotech company, a pioneer in the exploitation of the unknown or little-known part of biodiversity.
  • DEINOVE, located in the Euromdecine science park in Montpellier, employs 56 people, mainly researchers, engineers and technicians, and has filed over 350 patent applications internationally.

AseptiScope Announces that Data Presented at October Medical Congresses Support the Use of Aseptic Disk Covers to Protect Against Contaminated Stethoscopes

Retrieved on: 
Giovedì, Ottobre 22, 2020
Medical specialties, Microbiology, Branches of biology, Clostridiaceae, Gram-positive bacteria, Medical equipment, Sound technology, Stethoscope, Asepsis, Barrier isolator, Clostridioides difficile, Clostridioides

Dr. Frank Peacock, a co-founder of AseptiScope and a co-author of the study featured at the IDSA entitled Effectiveness of Aseptic Stethoscope Barriers in Allowing Clean Contact for Clostridioides Difficile-Contaminated Stethoscope, commented "this important study builds on a body of data supporting the use of aseptic disk covers to protect patients from exposure to pathogens on the stethoscope.

Key Points: 
  • Dr. Frank Peacock, a co-founder of AseptiScope and a co-author of the study featured at the IDSA entitled Effectiveness of Aseptic Stethoscope Barriers in Allowing Clean Contact for Clostridioides Difficile-Contaminated Stethoscope, commented "this important study builds on a body of data supporting the use of aseptic disk covers to protect patients from exposure to pathogens on the stethoscope.
  • "We are pleased to see these two prestigious congresses focus on the longstanding challenge of stethoscope hygiene," said Scott Mader the CEO and co-founder of AseptiScope.
  • "The findings further substantiate the stethoscope contamination challenge while supporting the use and effectiveness of touch-free, aseptic, single-use stethoscope disk covers.
  • With the upcoming launch of our flagship product, The DiskCover System, we look forward to bringing important innovation to this market," he added.

FDA Approves Merck’s DIFICID® (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older

Retrieved on: 
Lunedì, Gennaio 27, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Medicine, Medical specialties, Infectious diseases, RTT, Feces, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Fidaxomicin, Diarrhea, Antibiotic, Clostridioides, Merck

To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by Clostridioides difficile (C. difficile).

Key Points: 
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by Clostridioides difficile (C. difficile).
  • DIFICID is contraindicated in patients who have known hypersensitivity to fidaxomicin or any other ingredient in DIFICID.
  • C. difficile is an important cause of health care- and community-associated diarrheal illness in children, and sustained cure is difficult to achieve in some patients.
  • I am very excited to have a new C. difficile infection treatment option for my pediatric patients.

Acurx's Novel Lead Antibiotic Candidate Presented at Two Prominent International Scientific Conferences

Retrieved on: 
Giovedì, Ottobre 3, 2019
Microorganisms, Microbiology, Bacteriology, Clostridiaceae, Gram-positive bacteria, Environmental microbiology, Clostridioides, Antibiotic, -bacter, Gut flora, Bacteroidetes, Infection

This differential was especially pronounced among the phyla, Bacteroidetes and Firmicutes which generally comprise up to 90% of the healthy human gut microbiome."

Key Points: 
  • This differential was especially pronounced among the phyla, Bacteroidetes and Firmicutes which generally comprise up to 90% of the healthy human gut microbiome."
  • The abstract will be published as an online supplement to Open Forum Infectious Diseases (OFID), the Open Access Journal from IDSA.
  • Complete study results are in preparation for submission to a scientific journal.
  • In a poster entitled "Time-kill Kinetics of the Novel Antibacterial Agent ACX-362E against Clostridioides difficile" results were presented demonstrating rapid bacterial killing and potent bactericidal activity.

Microbiota Restoration Takes the Podium at DDW 2019: Investigational Microbiota-Based Therapies for Recurrent C. diff Highlighted

Retrieved on: 
Venerdì, Maggio 17, 2019
Health, Biotechnology, Pharmaceutical, Research, Science, Bacteria, Microorganisms, Infectious diseases, Clostridiaceae, Gram-positive bacteria, Pathogenic bacteria, Diarrhea, C. Diff, Clostridioides difficile infection, Clostridioides, Infection, Clostridium

One of the unmet needs, especially regarding recurrent C. diff infection, is the lack of standardized formulations that could be options for patients.

Key Points: 
  • One of the unmet needs, especially regarding recurrent C. diff infection, is the lack of standardized formulations that could be options for patients.
  • We are excited to present the data from these two investigational trials, as we believe these findings are an important step in the assessment of investigational microbiome-based therapies.
  • Details for the presentation are as follows:
    RBX2660 is currently in Phase 3 clinical development for the prevention of recurrent Clostridioides (Clostridium) difficile (C. diff) infection.
  • For more information on Rebiotix and its pipeline of human microbiome-directed therapies for diverse disease states, visit www.rebiotix.com .